Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
33
COLL Quote, Financials, Valuation and Earnings
Last price:
$29.69
Seasonality move
:
4.71%
Day range:
$29.53 - $31.06
52-week range:
$28.97 - $42.29
Dividend yield:
0%
P/E ratio:
12.75x
P/S ratio:
2.28x
P/B ratio:
4.09x
Volume:
1.3M
Avg. volume:
546.1K
1-year change:
-0.44%
Market cap:
$957.8M
Revenue:
$566.8M
EPS (TTM):
$2.33
Analysts' Opinion
-
Consensus RatingCollegium Pharmaceutical has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Collegium Pharmaceutical has an estimated upside of 42.26% from its current price of $29.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $29.70.
Fair Value
-
According to the consensus of 0 analysts, Collegium Pharmaceutical has 42.26% upside to fair value with a price target of -- per share.
COLL vs. S&P 500
-
Over the past 5 trading days, Collegium Pharmaceutical has overperformed the S&P 500 by 0.71% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Collegium Pharmaceutical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Collegium Pharmaceutical has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Collegium Pharmaceutical reported revenues of $159.3M.
Earnings Growth
-
Collegium Pharmaceutical earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Collegium Pharmaceutical reported earnings per share of $0.27.
Enterprise value:
1.7B
EV / Invested capital:
1.55x
Price / LTM sales:
2.28x
EV / EBIT:
8.59x
EV / Revenue:
2.85x
PEG ratio (5yr expected):
0.01x
EV / Free cash flow:
8.86x
Price / Operating cash flow:
7.09x
Enterprise value / EBITDA:
4.92x
Gross Profit (TTM):
$373.7M
Return On Assets:
7.23%
Net Income Margin (TTM):
14.78%
Return On Equity:
42.3%
Return On Invested Capital:
9.91%
Operating Margin:
21.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $361.7M | $546.6M | $599.2M | $136.7M | $159.3M | |
| Gross Profit | $158.4M | $281.3M | $373.7M | $80.3M | $96.8M | |
| Operating Income | -$8M | $117M | $193.5M | $45M | $34.8M | |
| EBITDA | $100.5M | $262.8M | $346.7M | $86.7M | $75.7M | |
| Diluted EPS | -$1.26 | $0.15 | $2.33 | $0.53 | $0.27 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $262.1M | $363.2M | $405.2M | $537.1M | $443.8M | |
| Total Assets | $643.8M | $741.8M | $1.2B | $1.2B | $1.6B | |
| Current Liabilities | $242.4M | $269M | $414.5M | $464.6M | $459.4M | |
| Total Liabilities | $471.2M | $490.7M | $1B | $998.7M | $1.4B | |
| Total Equity | $172.7M | $251.1M | $197.2M | $178.9M | $234.3M | |
| Total Debt | $267M | $261.7M | $723.6M | $711M | $867.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $94.1M | $267.7M | $193.7M | $74M | -$9M | |
| Cash From Investing | -$573.3M | -$46.7M | -$301.1M | -$3.8M | -$249M | |
| Cash From Financing | $420M | -$98.2M | -$87.2M | -$95.4M | $149M | |
| Free Cash Flow | $92.9M | $266.5M | $192.4M | $74M | -$9.2M | |
COLL
Sector
Market Cap
$957.8M
$44.6M
Price % of 52-Week High
70.23%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-0.44%
-29.09%
Beta (5-Year)
0.798
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$30.30
200-day SMA
Sell
Level
$34.96
Bollinger Bands (100)
Sell
Level
31.62 - 38.24
Chaikin Money Flow
Sell
Level
-1.7M
20-day SMA
Sell
Level
$30.46
Relative Strength Index (RSI14)
Sell
Level
40.90
ADX Line
Sell
Level
0.82
Williams %R
Buy
Level
-90.0901
50-day SMA
Sell
Level
$32.57
MACD (12, 26)
Sell
Level
-0.58
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
31M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.3739)
Sell
CA Score
(Annual)
Level (-1.177)
Buy
Beneish M-Score
(Annual)
Level (-3.5369)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.2433)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Stock Forecast FAQ
In the current month, COLL has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The COLL average analyst price target in the past 3 months is --.
-
Where Will Collegium Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Collegium Pharmaceutical share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Collegium Pharmaceutical?
Analysts are divided on their view about Collegium Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Collegium Pharmaceutical is a Sell and believe this share price will drop from its current level to --.
-
What Is Collegium Pharmaceutical's Price Target?
The price target for Collegium Pharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is COLL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Collegium Pharmaceutical is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of COLL?
You can purchase shares of Collegium Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Collegium Pharmaceutical shares.
-
What Is The Collegium Pharmaceutical Share Price Today?
Collegium Pharmaceutical was last trading at $29.69 per share. This represents the most recent stock quote for Collegium Pharmaceutical. Yesterday, Collegium Pharmaceutical closed at $29.70 per share.
-
How To Buy Collegium Pharmaceutical Stock Online?
In order to purchase Collegium Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
